Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Fujian Green Pine
300132
5
Yili Chuanning Biotechnology
301301
(Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating cash flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 219.63%342M | -41.52%1.15B | -10.85%674M | -34.05%459M | -176.52%-88M | -73.45%107M | 70.86%1.97B | 587.27%756M | 31.57%696M | 945.45%115M |
Net income from continuing operations | -36.36%154M | 4.11%887M | -3.04%255M | 2.26%181M | 4.50%209M | 14.15%242M | -5.12%852M | -4.71%263M | 7.27%177M | 19.76%200M |
Operating gains losses | 85.71%-2M | ---- | ---- | -91.30%2M | 100.00%2M | -131.11%-14M | -65.45%38M | -19.23%-31M | -25.81%23M | -98.89%1M |
Other non cash items | 193.33%14M | -74.19%-54M | -36.00%16M | -311.76%-36M | 26.92%-19M | 68.09%-15M | 78.01%-31M | 377.78%25M | 525.00%17M | -766.67%-26M |
Change in working capital | 222.22%154M | -76.96%238M | -22.66%372M | -36.46%291M | -278.48%-299M | -172.83%-126M | 455.38%1.03B | 414.38%481M | 46.79%458M | 70.74%-79M |
-Change in receivables | 591.55%349M | 3.15%-769M | 69.25%1.7B | -78.69%-2.58B | 135.47%183M | -143.83%-71M | -23.29%-794M | -15.26%1.01B | -5.63%-1.45B | -2.99%-516M |
-Change in loss and loss adjustment expense reserves | -151.23%-83M | -7.06%1.23B | -118.00%-763M | 64.68%2.1B | -166.75%-277M | 775.00%162M | 19.28%1.32B | 44.62%-350M | 1.83%1.28B | 2.22%415M |
-Change in payables and accrued expense | -50.93%-163M | -96.69%5M | -102.36%-429M | 23.33%444M | -22.83%98M | 12.90%-108M | 31.30%151M | 35.95%-212M | -8.86%360M | 108.20%127M |
-Change in other current assets | -57.89%24M | 152.63%10M | -75.00%11M | 43.48%-13M | 48.86%-45M | 18.75%57M | 86.23%-19M | 76.00%44M | 63.49%-23M | 12.87%-88M |
-Change in other current liabilities | 64.29%-15M | -312.50%-153M | 52.63%-135M | -49.85%167M | -375.00%-143M | -50.00%-42M | 204.35%72M | -235.29%-285M | 11,000.00%333M | 1,140.00%52M |
-Change in other working capital | 133.87%42M | -126.23%-80M | -104.66%-13M | 490.91%172M | -66.67%-115M | -189.21%-124M | 266.67%305M | 188.29%279M | -148.35%-44M | 46.92%-69M |
Cash from discontinued operating activities | ||||||||||
Operating cash flow | 219.63%342M | -41.52%1.15B | -10.85%674M | -34.05%459M | -176.52%-88M | -73.45%107M | 70.86%1.97B | 587.27%756M | 31.57%696M | 945.45%115M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 114.84%23M | -77.05%95M | 53.33%-21M | 34.07%122M | -49.49%149M | -312.33%-155M | 139.39%414M | -509.09%-45M | 116.22%91M | -51.64%295M |
Net investment purchase and sale | -456.76%-132M | -45.40%362M | 373.33%41M | -44.86%-930M | 3.50%1.21B | -74.83%37M | 180.17%663M | 93.70%-15M | -18.23%-642M | 85.31%1.17B |
Net proceeds payment for loan | 54.32%-37M | -541.18%-150M | -2,700.00%-26M | 700.00%8M | ---51M | -353.13%-81M | 121.94%34M | 0.00%1M | -93.75%1M | --0 |
Net business purchase and sale | 398.63%218M | 95.67%-9M | ---9M | 45.09%1.08B | -17.27%-1.01B | 22.34%-73M | -1,980.00%-208M | --0 | 3,072.00%743M | -716.19%-857M |
Net other investing changes | ---1M | 16.67%-5M | --1M | -25.00%-5M | ---- | ---- | -50.00%-6M | --0 | -100.00%-4M | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 114.84%23M | -77.05%95M | 53.33%-21M | 34.07%122M | -49.49%149M | -312.33%-155M | 139.39%414M | -509.09%-45M | 116.22%91M | -51.64%295M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -450.00%-495M | 47.51%-1.07B | 19.52%-569M | 31.41%-380M | 90.32%-27M | 81.67%-90M | -49.23%-2.03B | -1,544.19%-707M | -292.91%-554M | 66.59%-279M |
Net issuance payments of debt | ---- | --0 | --0 | --0 | --0 | --0 | 95.60%-21M | --0 | --0 | 98.69%-5M |
Net common stock issuance | -1,016.67%-55M | 108.59%17M | 107.14%4M | 103.61%3M | 110.26%4M | 130.00%6M | -4,060.00%-198M | -1,966.67%-56M | -4,050.00%-83M | -1,075.00%-39M |
Cash dividends paid | 13.06%-233M | -15.20%-788M | -116.67%-403M | -11.54%-58M | -11.32%-59M | 31.81%-268M | 43.61%-684M | 16.96%-186M | -10.64%-52M | 92.70%-53M |
Net other financing charges | -220.35%-207M | 73.85%-295M | 63.44%-170M | 22.43%-325M | 115.38%28M | 377.42%172M | -448.15%-1.13B | -312.33%-465M | -370.79%-419M | -167.41%-182M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -450.00%-495M | 47.51%-1.07B | 19.52%-569M | 31.41%-380M | 90.32%-27M | 81.67%-90M | -49.23%-2.03B | -1,544.19%-707M | -292.91%-554M | 66.59%-279M |
Net cash flow | ||||||||||
Beginning cash position | 14.78%1.41B | 40.48%1.23B | 8.27%1.32B | 13.46%1.12B | 26.84%1.09B | 40.48%1.23B | -59.08%872M | 53.78%1.22B | 2.17%988M | -27.43%857M |
Current changes in cash | 5.80%-130M | -48.73%181M | 2,000.00%84M | -13.73%201M | -74.05%34M | -820.00%-138M | 128.04%353M | -94.87%4M | 234.68%233M | 161.21%131M |
End cash position | 17.39%1.28B | 14.78%1.41B | 14.78%1.41B | 8.27%1.32B | 13.46%1.12B | 26.84%1.09B | 40.48%1.23B | 40.48%1.23B | 53.78%1.22B | 2.17%988M |
Free cash flow | 219.63%342M | -41.52%1.15B | -10.85%674M | -34.05%459M | -176.52%-88M | -73.45%107M | 70.86%1.97B | 587.27%756M | 31.57%696M | 945.45%115M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |